AHFS November 2025 Update

This update contains 6 new monographs, 36 revised monographs.

New monographs: Aceclidine Hydrochloride; Brensocatib; Pentazocine Hydrochloride and Naloxone Hydrochloride; Rilzabrutinib; Sepiapterin; Zopapogene Imadenovec-drba.

Revised monographs: Alglucosidase Alfa; Amphetamine; Atrasentan Hydrochloride; Azilsartan Kamedoxomil; Belzutifan; Clesrovimab-cfor; Clozapine; Codeine; COVID-19 Vaccine, Adjuvanted (Novavax)(2025-2026 Formula); COVID-19 Vaccine, mRNA (Moderna) (2025-2026 Formula); COVID-19 Vaccine, mRNA (Pfizer-BioNTech)(2025-2026 Formula); Deuruxolitinib Phosphate; Dextroamphetamine; Dihydroergotamine Mesylate; Dupilumab; Guselkumab; Imiglucerase; Influenza Vaccine Inactivated; Influenza Vaccine Live Intranasal; Influenza Vaccine Recombinant; Insulin Glargine; Lecanemab-irmb; Levothyroxine Sodium; Loncastuximab Tesirine-lpyl; Nilotinib; Paliperidone; Respiratory Syncytial Virus Vaccine; Respiratory Syncytial Virus Vaccine (mRNA); Respiratory Syncytial Virus Vaccine, Adjuvanted; Rocuronium Bromide; Roflumilast (Topical); Sodium Nitroprusside; Taletrectinib Adipate; Tranexamic Acid; Upadacitinib; Von Willebrand Factor (Recombinant).